KisoJi Biotechnology Inc.

KisoJi is a next-generation antibody company developing multi-specific antibodies to improve outcomes in oncology. Using next generation sequencing, machine learning and transgenic technologies, KisoJi has developed a powerful new multi-specific antibody discovery platform that is driven by epitope mapping, enabling deliberate antibody design and engineering. Our lead product is a tri-specific antibody that targets: the dopamine 2 receptor, PD1 and CD3, which can provide tumor targeting / signaling, checkpoint inhibition, and non-activating T-cell recruitment, respectively. Other antibodies targeting cancer metabolism, cytokines, and other tumor associated antigens are also in development in our multi-specific antibody pipeline.